Colfax Publicizes Public Providing Value of 14,000,000 NYSE Frequent Shares: CFX
ANNAPOLIS JUNCTION, MD, March 16, 2021 (GLOBE NEWSWIRE) – Colfax Company (“Colfax” or the “Firm”) (NYSE: CFX), a number one diversified know-how firm, at present introduced the award of a registered public providing of 14,000,000 shares of its frequent shares at a public providing value of $ 46.00 per share. The underwriters have a 30 day choice to buy as much as 2,100,000 extra shares of the Firm on the public providing value. The Firm estimates that the online proceeds of the Providing, after deducting underwriting reductions and commissions and different estimated bills of the Providing, can be roughly $ 618.4 million, or $ 711.3 million if the Underwriters train. their choice to buy extra shares in full. The shares are anticipated to be delivered round March 19, 2021, topic to customary closing circumstances.
The Firm intends to make use of the online proceeds of the Providing (after deduction of any subscription reductions and commissions and different estimated bills of the Providing payable by the Firm) for working capital and for different basic functions. of the enterprise, which can embrace, amongst different issues, capital expenditures. and debt reimbursement.
Goldman Sachs & Co. LLC and Evercore ISI are appearing as co-lead bookkeepers and underwriters’ representatives for the providing. Morgan Stanley and UBS Funding Financial institution are additionally appearing as co-bookkeepers for the providing. BofA Securities, Cowen, KeyBanc Capital Markets, Wells Fargo Securities, Baird, BMO Capital Markets, BNP Paribas, Residents Capital Markets, Scotiabank, SMBC Nikko, Stifel and UniCredit Capital Markets act as co-managers of the providing.
The providing is being made in accordance with a previous registration assertion on Type S-3, together with a base prospectus, which has been filed by Colfax with the Securities and Trade Fee (the “SEC”) and has taken impact routinely. when filed on February 18, 2021. A preliminary prospectus complement and associated prospectus referring to and describing the phrases of the provide have been filed with the SEC and can be found on the SEC’s web site at www. sec.gov. Copies of the Last Prospectus Complement and accompanying prospectus referring to the Supplied Securities may be obtained, when obtainable, from: Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Avenue, New York, NY 10282, by telephone at (866) 471-2526, or by e-mail at [email protected]; Evercore Group LLC, Attn: Fairness Capital Markets, 55 East 52nd Avenue, thirty sixth Flooring, New York, NY 10055, by telephone at (888) 474-0200, or by e-mail: [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus, 180 Varick Avenue, Second Flooring, New York, New York 10014; or UBS Securities LLC, Attn: Prospectus Service, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275, or by e-mail [email protected].
This press launch doesn’t represent a proposal to promote or the solicitation of a proposal to purchase such securities, nor any sale of such securities in any state or jurisdiction the place such a proposal, solicitation or sale can be illegal previous to the registration or qualification below the securities legal guidelines of these states or jurisdictions.
About Colfax Company
Colfax Company is a number one diversified know-how firm offering specialty medical applied sciences and manufacturing know-how services to prospects world wide, primarily below the DJO and ESAB manufacturers. Colfax believes that its manufacturers are among the many most acknowledged in every of the markets it serves. The Firm makes use of its Colfax Enterprise System (“CBS”), a complete set of instruments, processes and values, to create superior worth for patrons, shareholders and associates. Colfax frequent inventory trades on the New York Inventory Trade below the image “CFX”.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press launch accommodates forward-looking statements, together with forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. These forward-looking statements embrace, however are usually not restricted to, statements concerning the provide and meant use by Colfax of the product of the provide, plans, goals, expectations and intentions and different statements which don’t are usually not historic or present details. Ahead-looking statements are based mostly on Colfax’s present expectations and contain dangers and uncertainties that might trigger precise outcomes to vary materially from these expressed or implied in these forward-looking statements. Components that might trigger Colfax’s outcomes to vary materially from present expectations embrace, however are usually not restricted to, dangers associated to the affect of the worldwide COVID-19 pandemic, together with actions of governments, firms and people in response to the state of affairs, such because the extent and period of the epidemic, the character and effectiveness of presidency actions and restrictive measures applied in response, important delays and cancellations of medical procedures , provide chain disruptions, affect on prospects’ solvency and monetary viability, and different impacts on Colfax’s enterprise and talent to execute enterprise continuity plans, and different components detailed in Colfax’s studies filed with the SEC, together with its newest annual report on Type 10-Okay below “Danger Components”, in addition to different dangers mentioned within the paperwork ents deposited by Colfax with the second. As well as, these statements are based mostly on assumptions which can be topic to vary. This press launch is just legitimate as of the date hereof. Colfax disclaims any obligation to replace the knowledge herein.
Vice President, Finance